Lung Cancer

Nuvalent submitted an NDA for neladalkib to the FDA for patients with previously treated ALK-positive non-small cell lung cancer, based on ALKOVE-1 trial data showing activity.

New research shows adults over 80 with early-stage lung cancer can achieve surgical outcomes and quality of life comparable to younger patients.

New ELCC 2026 data show longer survival, better brain metastases control and more personalized treatment options for patients with lung cancer.

Eight patients with NSCLC treated with ateganosine plus Libtayo had over 2-year survival after prior therapies, based on phase 2 THIO-101 trial data.

Black patients with early-stage lung cancer were less likely to receive curative treatment than White patients, despite all having Medicare coverage, study finds.

Hernexeos led to high response rates and disease control in HER2-mutant NSCLC, including patients with brain metastases, with manageable safety.

Tagrisso combined with chemotherapy improved how long patients with EGFR- and TP53-mutant NSCLC lived without their cancer worsening compared with Tagrisso alone.

KRAS G12d-targeted protein degrader setidegrasib demonstrated antitumor activity and a manageable safety profile in patients with KRAS G12d-mutant non–small cell lung cancer.

Zegfrovy helped patients live longer without cancer growth and improved tumor response compared with chemotherapy in first-line lung cancer treatment.

New FDA approvals target mutations in lung cancer, improving outcomes, while clinicians refine strategies to manage immunotherapy-related side effects.

Black Medicare patients with early-stage NSCLC continue to get surgery and radiation at lower rates than White patients, showing persistent treatment gaps.

FDA declined approval of retifanlimab for metastatic non–small cell lung cancer due to manufacturing issues at a third-party facility, not safety concerns.

February 2026 coverage highlighted combination EGFR therapy guidance, chemo-free treatment options, biomarker testing and survivorship lung health.

Four new and ongoing lung cancer trials are enrolling patients, offering options in first-line and previously treated NSCLC settings.

FDA approved Hernexeos for untreated HER2-mutant NSCLC after 76% of patients had tumor shrinkage in clinical trial data.

Lung Cancer Voices Summit Calls on Congress: Support Research. Save Lives.

Heather Quintana Suchan shares how work and music community support her while she lives fully with stage 4 lung cancer.

This device detects and characterizes lesions on low-dose CT scans, helping patients with cancer get faster, tailored care and avoid unnecessary procedures.

Looking back over the setbacks and blessings of the roller coaster ride that was my cancer treatment journey.

The FDA approved a once-monthly Rybrevant Faspro schedule with Lazcluze for first-line EGFR-mutated advanced NSCLC, reducing visits.

Patients with stage 4 lung cancer and EGFR mutations may benefit from combination therapies that improve disease control.

Retevmo improved event-free survival in stage 2 to 3A RET fusion-positive non-small cell lung cancer after curative therapy, per phase 3 data.

Heather Quintana Suchan says early biomarker testing at diagnosis helped match her to Rybrevant and urges patients to personalize care and stay active during treatment.

Heather Quintana Suchan, a nonsmoker with stage 4 lung cancer, credits genomic testing and Rybrevant and urges others not to ignore mild symptoms.